This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Taliglucerase alfa for Gaucher disease – first line

< Back

Taliglucerase alfa for Gaucher disease – first line


Endocrine, Nutritional and Metabolic

December 2010

Taliglucerase alfa is a plant cell expressed recombinant form of glucocerebrosidase produced in transformed carrot root cells. It is intended as a substitute enzyme replacement therapy (ERT) for the first line treatment of patients with Type 1 Gaucher disease. Taliglucerase alfa is administered by intravenous (IV) infusion at a starting dose range of 30U/kg to 60U/kg of body weight, given over 1 to 2 hours once every 2 weeks. Dosage may be adjusted depending on the individual patient.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts